Filing Details

Accession Number:
0001818382-22-000160
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-09-19 16:34:45
Reporting Period:
2022-09-15
Accepted Time:
2022-09-19 16:34:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1818382 Humacyte Inc. HUMA Biological Products, (No Disgnostic Substances) (2836) 851763759
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1878020 W Brady Dougan 2525 East North Carolina Highway 54
Durham NC 27713
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-09-15 1,522,500 $4.00 18,930,004 No 4 S Indirect By Ayabudge LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Ayabudge LLC
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 510,161 Direct
Common Stock 1,158,240 Indirect By spouse
Footnotes
  1. The sale was made by Ayabudge LLC, an entity controlled by Brady W Dougan, in a block trade. The purchaser is an existing investor of the Issuer, who had previously participated in the Issuer's PIPE financing transaction, and was interested in increasing its ownership of the Humacyte, Inc. The transaction enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchaser to acquire a large block of shares at a time that Humacyte, Inc. was not conducting a financing and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer.